Rentschler Biopharma appoints Tobias Glueck as SVP Human Relations

Rentschler Biopharma appoints Tobias Glueck as
Senior Vice President Human Relations

Laupheim, Germany, October 13, 2022 – Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Tobias Glueck has joined the Company as Senior Vice President Human Relations. He leads the global HR team and is responsible for developing and coordinating HR activities at all three sites: Laupheim, Germany; Milford, MA, USA and Stevenage, UK. Tobias Glueck brings more than 25 years of human resources experience and has worked as an executive in both the U.S. and Germany.

He joins Rentschler Biopharma from Novartis Germany GmbH, where he served as Managing Director People & Organization, covering the full HR scope of the Pharma Business Unit and led all cross-divisional HR activities in Germany. He drove new corporate culture initiatives, initiated pilot programs to improve employee experience and significantly increased the number of people moves across the organization with a strong focus on diverse and international talents. Prior to that, Tobias Glueck was Vice President Human Resources at Cameron, a Schlumberger company, first in the Subsea Systems division and later in the Surface Systems division.  For this leading oilfield services company, he was based in the U.S. with HR responsibility for sites around the globe. In these positions, he successfully drove recruitment and retention activities, oversaw various transformation projects, and implemented and improved development programs. 

“I am excited to welcome Tobias Glueck to the Rentschler team. Tobias’ extensive international experience and expertise in diverse organizations align perfectly with our business strategy and focus on sustainable growth and long-term value creation. He knows the life sciences sector well, and his ability to navigate local cultures with a deep understanding of the industry will serve us well as our business expands,” said Dr. Frank Mathias, CEO of Rentschler Biopharma. “Our people are the heart of our success, and I look forward to Tobias driving our efforts to continually attract and retain highly qualified personnel.”

Tobias Glueck, Senior Vice President Human Relations, added: “It is my pleasure to be part of a team where we all share a clear vision of advancing medicine to save peoples‘ lives. I am impressed with the long legacy of Rentschler Biopharma as a family-owned business, while being an internationally active and globally successful leader. Strong collaboration paired with a positive corporate culture and employee experience were at the core of my career to date. In that spirit, I especially look forward to working with teams at each of our three sites to help address their specific people needs while we aim to grow the business and win new clients. Rentschler Biopharma has been constantly progressing, and we will continue to invest in our most valuable asset – our people.”

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,100 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

For further information, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook.

Contact:
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
Phone: +49-7392-701-874
communications@rentschler-biopharma.com

Media inquiries:
MC Services AG
Eva Bauer
Phone: +49-89-210228-0
rentschler@mc-services.eu

U.S.
Laurie Doyle
Phone: +1-339-832-0752

For a high-resolution image, please contact communications@rentschler-biopharma.com.